United States Diabetes Devices Market Growth, Share (2022-27)
Market Overview
The United States Diabetes Devices Market is expected to register a CAGR greater than 6.5% over the forecast period, 2022–2027.
Since the start of the epidemic, the United States has recorded 79 million cases of COVID-19. Over 960,000 people have died in the United States because of COVID-19. The average number of new COVID-19 cases per day has decreased to 40,000, approximately 30,000 less than it was a week ago, according to CDC data. In January 2021, after the FDA had authorized COVID-19 vaccines for emergency use the month before, people in the U.S. began to be vaccinated. By March, the daily number of new infections had steeply declined, and April through June saw those numbers go down even further. But by July, the arrival and spread of the delta coronavirus variant sparked another surge in cases of COVID-19.
Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. People with diabetes face a higher chance of experiencing serious complications from COVID-19. Doctors and the government are asking diabetes patients to check their glucose levels continuously. In general, people with diabetes are more likely to experience severe symptoms and complications when infected with a virus. According to the AACE (American Association of Clinical Endocrinologists), recent studies have shown that of those hospitalized for severe disease, 22.2–26.9% reported living with diabetes. Diabetes and high glucose levels are associated with increased complications, respiratory failure, and mortality in hospitalized patients with coronavirus.
The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the diabetes care device market’s growth.
Scope of the Report
The United States Diabetes Devices Market is segmented into Management Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, Jet Injectors), and Monitoring Devices (Self-monitoring Blood Glucose, Continuous Glucose Monitoring). The report offers the value (in USD million) for the above segments. Read Full Report
Comments
Post a Comment